Invention Grant
- Patent Title: Integrin interaction inhibitors for the treatment of cancer
- Patent Title (中): 用于治疗癌症的整联蛋白相互作用抑制剂
-
Application No.: US13636010Application Date: 2011-03-21
-
Publication No.: US08853149B2Publication Date: 2014-10-07
- Inventor: Lori Hazlehurst , Mark McLaughlin , Priyesh Jain , William S. Dalton
- Applicant: Lori Hazlehurst , Mark McLaughlin , Priyesh Jain , William S. Dalton
- Applicant Address: US FL Tampa US FL Tampa
- Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.,University of South Florida
- Current Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.,University of South Florida
- Current Assignee Address: US FL Tampa US FL Tampa
- Agency: Saliwanchik, Lloyd & Eisenschenk
- International Application: PCT/US2011/000512 WO 20110321
- International Announcement: WO2011/115688 WO 20110922
- Main IPC: A61K38/00
- IPC: A61K38/00 ; C07K7/06
Abstract:
Integrin interaction inhibitors using a beta-turn promoter are described herein. These peptides are useful in treating cancer, such as multiple myeloma, by administering a therapeutically effective amount of the integrin interaction inhibitor. Data show that integrin interaction inhibitors act synergistically or additively interact with anti-proliferative agents such as doxorubicin, SAHA, arsenic trioxide, and etoposide.
Public/Granted literature
- US20130065837A1 INTEGRIN INTERACTION INHIBITORS FOR THE TREATMENT OF CANCER Public/Granted day:2013-03-14
Information query
IPC分类:
